Modulation of co-inhibitory and co-stimulatory immune checkpoint pathway activity with antibody-based therapies has emerged as a promising anti- 
In humans, adoptive transfer of tumour-infiltrating lymphocytes (TILs) with concomitant administration of interleukin-2 (IL-2) mediates tumour regression in 34-40% of patients with advanced melanoma [9] . Efforts have been focused for some time on the characterisation of antigens recognised by TILs.
Melanoma TILs have been demonstrated to recognise shared antigens on melanoma cell lines established from different patients, in a class I majorhistocompatibility complex (MHC)-restricted manner in vitro [10, 11] . The first gene identified to code for an antigen recognised on human tumours by autologous TILs was MAGE-1, silent in normal tissues except in testes, and expressed by a number of other solid tumour subtypes [12] . Subsequently, three further self-proteins, all melanoma/melanocyte lineage-specific, encoded by MART-1, tyrosinase and gp100, were identified [13] [14] [15] . Although these 'public' tumour-associated antigens appeared attractive targets for both adoptive cell-based and vaccination strategies, neither approach was observed to yield particularly promising activity in the clinical setting [reviewed in 16] .
The identification of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a co-inhibitory immune checkpoint molecule, followed by the demonstration of efficient rejection of established murine tumours with CTLA-4 'blockade', highlighted immune regulation as a potential contributor to the limited clinical activity of therapeutic strategies directed against these tumour-associated antigens [17, 18] . In a pooled analysis of patients with advanced melanoma treated with ipilimumab, an antibody directed against CTLA-4, three-year survival was found to range between 20 and 26% [19] . Amongst a cohort of 107 patients with advanced melanoma, one of the earliest to be treated with nivolumab, an anti-PD-1 antibody, 5-year survival was recently reported as 34% (Hodi S., AACR, 2016). Whilst this is remarkable in a solid tumour subtype many deemed 'untreatable', it is important to acknowledge that the majority of patients do not respond to these forms of immune checkpoint blockade, at least as monotherapy. The search for predictive biomarkers in this setting has been challenging, however the identification of an inextricable relationship between the genomic landscape and anti-tumour immunity has served to re-highlight the importance of identifying the most relevant substrates for T cell recognition, whilst simultaneously addressing regulation at the tumour site.
The search for clinically relevant targets of immune response has shifted focus more recently. Tumour-specific mutations may serve as 'private' neoantigens, eliciting anti-tumour T cell responses [20] [21] [22] [23] . In contrast to nonmutated self antigens, these are thought to be of particular relevance in tumour control, since the quality of the T cell pool available for these antigens is not affected by central T cell tolerance [24] . Antibody-mediated blockade of In an era of personalised medicine, these findings serve, at the very least, to help better identify those most likely to derive benefit from checkpoint blockade, allowing improved patient stratification. Importantly, they also move the tumour immunology field a step closer to the ultimate goal of achieving durable remissions for the majority, rather than a select few.
